Evaluation of novel protease inhibitors against darunavir-resistant variants of HIV type 1.

FEBS Open Bio · 2017 · PMC5221448 · PMID 28097091

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

might not be significantno p-value reported

Some of the IC 50 values were relatively different from those of the five PIs for inhibiting the replication of AE‐Gag/PR‐recombinant HIV‐1 in our previous report (Table 5 ) 20 ; however, the difference might not be significant for evaluating PIs.

also in 673 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.